HAE (Haemonetics) Other Current Liabilities: $164 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

HAE Haemonetics Corp HAE
85 GF Score
Price $104.65
GF Value $85.31
Valuation Modestly Overvalued
! 4 Warning Signs
View Full Analysis

What is Haemonetics Other Current Liabilities?

Haemonetics HAE +15.93% 85 Other Current Liabilities is $164 Mil as of Jun. 2026. GuruFocus rates HAE with a GF Score™ of 85/100 and a GF Value™ of $85.31 (Modestly Overvalued). The stock has 4 warning signs investors should review.

Haemonetics's other current liabilities for the quarter that ended in Jun. 2026 was $164 Mil.

Haemonetics's quarterly other current liabilities declined from Dec. 2025 ($134 Mil) to Mar. 2026 ($116 Mil) but then increased from Mar. 2026 ($116 Mil) to Jun. 2026 ($164 Mil).

Haemonetics's annual other current liabilities declined from Mar. 2024 ($105 Mil) to Mar. 2025 ($105 Mil) but then increased from Mar. 2025 ($105 Mil) to Mar. 2026 ($116 Mil).

Haemonetics Other Current Liabilities Related Terms

Haemonetics Other Current Liabilities Historical Data

* Premium members only.

The historical data trend for Haemonetics's Other Current Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Haemonetics Other Current Liabilities Chart

Haemonetics Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Other Current Liabilities
Get a 7-Day Free Trial Premium Member Only Premium Member Only 94.40 81.42 104.85 104.79 116.03

Haemonetics Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Other Current Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 145.64 134.02 134.33 116.03 163.80
HAE
85GF Score
Haemonetics Corp HAE
Other Current Liabilities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Haemonetics Other Current Liabilities Calculation

The liability a company needs to pay in the next 12 months, but not assigned to Accounts Payable or Debt. For instance, Wal-Mart (WMT) has accrued wages, salaries, valuation, bonuses, insurance liabilities, accrued tax etc. These are all included in other current liabilities.

What does a Other Current Liabilities of $164 Mil mean?
Haemonetics (HAE) has a Other Current Liabilities of $164 Mil as of Jun. 2026. Other current liabilities as record on a company's balance sheet not categorized as standard liabilities. View historical data on Haemonetics.
Is Haemonetics' Other Current Liabilities too high?
Haemonetics' current Other Current Liabilities is $164 Mil. Overall, Haemonetics has a GF Score™ of 85/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Haemonetics' Other Current Liabilities compare to IRTC and ITGR?
Haemonetics' Other Current Liabilities of $164 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Current Liabilities for a Medical Devices & Instruments company?
A good Other Current Liabilities depends on the Medical Devices & Instruments industry context. However, Other Current Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Current Liabilities mean?
A high Other Current Liabilities can signal that a stock is expensive relative to its fundamentals. Other current liabilities as record on a company's balance sheet not categorized as standard liabilities. View historical data on Haemonetics. Haemonetics's current Other Current Liabilities is $164 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Haemonetics stock overvalued right now?
Based on GuruFocus' analysis, Haemonetics (HAE) is currently considered Modestly Overvalued. The stock's GF Value™ is $85.31, compared to a current price of $104.65 — trading 22.7% above its estimated fair value. The current Other Current Liabilities is $164 Mil. Haemonetics' overall GF Score™ is 85/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Current Liabilities calculated?
Other Current Liabilities is calculated from a company's financial statements. For Haemonetics (HAE), the current Other Current Liabilities is $164 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Haemonetics (HAE) Overvalued in 2026?

Based on GuruFocus' analysis, Haemonetics stock appears to be overvalued. The current stock price of $104.65 is trading 22.7% above its estimated GF Value™ of $85.31. GuruFocus considers Haemonetics to be Modestly Overvalued.

Key valuation signals for HAE:

  • Other Current Liabilities: $164 Mil
  • GF Value™: $85.31 vs. price of $104.65 (22.7% above fair value)
  • GF Score™: 85/100 with 4 warning signs

No single metric tells the full story. See the HAE stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Haemonetics Business Description

Other Exchanges HAZ:Germany
Address 125 Summer Street, Boston, MA, USA, 02110
Haemonetics Corp aims to improve patient care and reduce the cost of healthcare by providing medical products and solutions in the blood and plasma component collection, surgical suite, and hospital transfusion service spaces. As such, the company operates under three segments: plasma, blood center, and hospital. The company emphasizes its plasma and hospital segments due to their robust growth potential, whereas the blood center segment tends to be constrained by higher competition. Product revenue is driven by demand for disposable blood component collection and processing sets and the related equipment needed for proper functionality.
85GF Score

Get the complete analysis for HAE

Other Current Liabilities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$104.65
Price
$85.31
GF Value